encorafenib

chemical compound

Uses your system voice; voice and rate in settings.

Q15409405Snapshot

≈ 3 min read

Names in other languages

  • DeutschEncorafenib
  • Englishencorafenib
  • Françaisencorafénib
  • עבריתאנקורפניב
  • 日本語エンコラフェニブ
  • shLGX818
  • СрпскиLGX818
  • 中文康奈非尼

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

{{Drugbox | image = Encorafenib.svg | image_class = skin-invert-image | width = 240 | alt = | caption = | pronounce = | tradename = Braftovi | Drugs.com = | MedlinePlus = a618040 | DailyMedID = Encorafenib | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_category= | routes_of_administration = By mouth | class = Antineoplastic agent | ATC_prefix = L01 | ATC_suffix = EC03 | ATC_supplemental = | legal_AU = | legal_AU_comment = | legal_BR = | legal_BR_comment = | legal_CA = Rx-only | legal_CA_comment = | legal_DE = | legal_DE_comment = | legal_NZ = | legal_NZ_comment = | legal_UK = | legal_UK_comment = | legal_US = Rx-only | legal_US_comment = | legal_EU = Rx-only | legal_EU_comment = | legal_UN = | legal_UN_comment = | legal_status = | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action = | excretion = | CAS_number = 1269440-17-6 | CAS_supplemental = | PubChem = 50922675 | PubChemSubstance = | IUPHAR_ligand = | DrugBank = DB11718 | ChemSpiderID = 28536139 | UNII = 8L7891MRB6 | KEGG = D11053 | ChEBI = | ChEMBL = 3301612 | NIAID_ChemDB = | PDB_ligand = | synonyms = LGX818 | IUPAC_name = Methyl [(2S)-1- {[4-(3- {5-chloro-2-fluoro-3-[(methylsulfonyl)amino]phenyl}-1-isopropyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino}-2-propanyl]carbamate | C=22 | H=27 | Cl=1 | F=1 | N=7 | O=4 | S=1 | SMILES = C[C@@H](CNc1nccc(n1)c…

{{Drugbox | image = Encorafenib.svg | image_class = skin-invert-image | width = 240 | alt = | caption = | pronounce = | tradename = Braftovi | Drugs.com = | MedlinePlus = a618040 | DailyMedID = Encorafenib | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_category= | routes_of_administration = By mouth | class = Antineoplastic agent | ATC_prefix = L01 | ATC_suffix = EC03 | ATC_supplemental = | legal_AU = | legal_AU_comment = | legal_BR = | legal_BR_comment = | legal_CA = Rx-only | legal_CA_comment = | legal_DE = | legal_DE_comment = | legal_NZ = | legal_NZ_comment = | legal_UK = | legal_UK_comment = | legal_US = Rx-only | legal_US_comment = | legal_EU = Rx-only | legal_EU_comment = | legal_UN = | legal_UN_comment = | legal_status = | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action = | excretion = | CAS_number = 1269440-17-6 | CAS_supplemental = | PubChem = 50922675 | PubChemSubstance = | IUPHAR_ligand = | DrugBank = DB11718 | ChemSpiderID = 28536139 | UNII = 8L7891MRB6 | KEGG = D11053 | ChEBI = | ChEMBL = 3301612 | NIAID_ChemDB = | PDB_ligand = | synonyms = LGX818 | IUPAC_name = Methyl [(2S)-1- {[4-(3- {5-chloro-2-fluoro-3-[(methylsulfonyl)amino]phenyl}-1-isopropyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino}-2-propanyl]carbamate | C=22 | H=27 | Cl=1 | F=1 | N=7 | O=4 | S=1 | SMILES = C[C@@H](CNc1nccc(n1)c2cn(nc2c3cc(cc(c3F)NS(=O)(=O)C)Cl)C(C)C)NC(=O)OC | StdInChI = 1S/C22H27ClFN7O4S/c1-12(2)31-11-16(17-6-7-25-21(28-17)26-10-13(3)27-22(32)35-4)20(29-31)15-8-14(23)9-18(19(15)24)30-36(5,33)34/h6-9,11-13,30H,10H2,1-5H3,(H,27,32)(H,25,26,28)/t13-/m0/s1 | StdInChI_comment = | StdInChIKey = CMJCXYNUCSMDBY-ZDUSSCGKSA-N | density = | density_notes = | melting_point = | melting_high = | melting_notes = | boiling_point = | boiling_notes = | solubility = | sol_units = | specific_rotation = }} Encorafenib, sold under the brand name Braftovi, is an anti-cancer medication used for the treatment of certain melanoma cancers. It is a small molecule BRAF inhibitor that targets key enzymes in the MAPK signaling pathway.

This pathway occurs in many different cancers including melanoma and colorectal cancers. The most common (≥25%) adverse reactions include fatigue, nausea, diarrhea, vomiting, abdominal pain, and arthralgia. Encorafenib was developed by Novartis and Array BioPharma.

In June 2018, it was approved by the FDA in combination with binimetinib for the treatment of people with unresectable or metastatic BRAF V600E or V600K mutation-positive melanoma.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1363730776 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.